Nordic Nanovector: Single administration Betalutin® is effective and well-tolerated in R/R iNHL patients: 6 month follow-up data presented at ASH
· Overall response rate (ORR) of 61% and complete response (CR) rate of 28% in 74 patients with indolent non-Hodgkin’s lymphoma (iNHL) · Highly active in follicular lymphoma (FL) patients with ≥2 prior therapies (n=37) (ORR 70% CR 32%), and rituximab-refractory FL (n=21) (ORR 62% CR 19%) · Durable responses, especially for patients with a CR (20.7 months) · Promising response rates (ORR and CR) for dosing regimens being evaluated in pivotal Phase 2b PARADIGME study · Well tolerated with predictable and manageable safety profile · Conference call/audio cast to discuss results to